Abstract:Abstract Background Osteoclasts are responsible for the bone loss in rheumatoid arthritis (RA). Hypoxia has been suggested to play key roles in pathological bone loss. However, the current understanding of the effects of hypoxia on osteoclastogenesis is controversial. Effects of hypoxia on both the formation and function of osteoclasts requires examination. In the current study, we aimed to explore the effect of hypoxia on osteoclast differentiation and the underlying mechanisms. Methods RAW264.7 cells and murine bone-marrow-derived monocytes were used to induce osteoclastogenesis in the presence of macrophage colony-stimulating factor (M-CSF) and receptor activator of nuclear factor kappa B ligand (RANKL). Hypoxic conditions were maintained in a hypoxic chamber at 5% CO2 and 1% O2, balanced with N2. Osteoclasts were detected by tartrate-resistant acid phosphatase (TRAP) staining. A bone resorption assay was carried out in vitro using bone slices. RT-PCR was conducted to detect osteoclast markers and transcription factors. The phosphorylation of nuclear factor-κBα (IκBα), c-Jun N-terminal kinase (JNK), extracellular regulated protein kinase (ERK), and p38 was detected by western blotting. Mann–Whitney U test or Student’s t test was used to compare differences between the two groups. Results TRAP staining and the bone resorption assay revealed that hypoxia-restrained osteoclast differentiation and bone resorption. Expression of osteoclast markers including cathepsin K, RANK, and TRAP decreased during osteoclast differentiation under hypoxic conditions (all P < 0.05). Hypoxia at 1% O2 did not affect cell viability, whereas it dramatically abated RANKL-dependent phosphorylation of the JNK-mitogen-activated protein kinases (MAPK) and IκBα pathways. Moreover, the expression of nuclear factor of activated T-cell cytoplasmic 1 (NFATc1) was inhibited under hypoxic conditions (all P < 0.05). Conclusions These results suggest that constant hypoxia at 1% O2 significantly restrains osteoclast formation and resorbing function without affecting cell viability. Constant hypoxia might inhibit RANKL-induced osteoclastogenesis by regulating NFATc1 expression via interfering the phosphorylation of JNK and IκBα.

Osteoblast Hypoxia-Inducible Factor-1 Alpha Pathway Activation Restrains Osteoclastogenesis Via The Interleukin-33-Microrna34a-Notch1 Pathway

Regulation of Interaction of Osteoblasts and Osteoclasts by Hypoxia/hypoxiainducible Factor-1Α Pathway

HIF-1α Disturbs Osteoblasts and Osteoclasts Coupling in Bone Remodeling by Up-Regulating OPG Expression

Osteocytic HIF-1α Pathway Manipulates Bone Micro-structure and Remodeling via Regulating Osteocyte Terminal Differentiation

Hypoxia-inducible factor 1α enhances RANKL-induced osteoclast differentiation by upregulating the MAPK pathway

HIF-1-mediated Expression of Foxo1 Serves an Important Role in the Proliferation and Apoptosis of Osteoblasts Derived from Children's Iliac Cancellous Bone

RhoA Promotes Osteoclastogenesis and Regulates Bone Remodeling Through Mtor-Nfatc1 Signaling.

Hif-1 Alpha Inhibits Wnt Signaling Pathway By Activating Sost Expression In Osteoblasts

[Regulation of Hypoxia Inducible Factor-1Alpha on Osteoblast Function in Osteogenesis].

Constant hypoxia inhibits osteoclast differentiation and bone resorption by regulating phosphorylation of JNK and IκBα

HIF-1α Regulates Bone Homeostasis and Angiogenesis, Participating in the Occurrence of Bone Metabolic Diseases

HIF-1α Inhibits Wnt Signaling Pathway by Activating Sost Expression in Osteoblasts

FOXO1 inhibits osteoclastogenesis partially by antagnozing MYC

RANKL-independent modulation of osteoclastogenesis

MicroRNA-183 increases osteoclastogenesis by repressing heme oxygenase-1

Synergistic Inhibition of Wnt Pathway by HIF-1α and Osteoblast-Specific Transcription Factor Osterix (osx) in Osteoblasts

Interleukin-3 Plays Dual Roles in Osteoclastogenesis by Promoting the Development of Osteoclast Progenitors but Inhibiting the Osteoclastogenic Process

Hypoxia Drives Material‐Induced Heterotopic Bone Formation by Enhancing Osteoclastogenesis via M2/Lipid‐Loaded Macrophage Axis

miR-134-5p inhibits osteoclastogenesis through a novel miR-134-5p/Itgb1/MAPK pathway

Combination Of Il-6 And Sil-6r Differentially Regulate Varying Levels Of Rankl-Induced Osteoclastogenesis Through Nf-Kappa B, Erk And Jnk Signaling Pathways

Autophagy Regulates Hypoxia‐induced Osteoclastogenesis Through the HIF‐1α/BNIP3 Signaling Pathway